Craig Hendrix
Overview
Explore the profile of Craig Hendrix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rael C, Giguere R, Bryndza Tfaily E, Sutton S, Horn E, Schieffer R, et al.
AIDS Res Hum Retroviruses
. 2024 May;
40(10):591-605.
PMID: 38753738
To improve current and future use of existing (oral, injectable) and potential future (implants, douches) pre-exposure prophylaxis (PrEP) products, we must understand product preferences relative to one another, among gay...
2.
Nair G, Celum C, Szydlo D, Brown E, Akello C, Nakalega R, et al.
Lancet HIV
. 2023 Oct;
10(12):e779-e789.
PMID: 37898146
Background: Half of new HIV acquisitions in Africa occur in adolescent girls and young women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine or the monthly dapivirine vaginal...
3.
Hughes J, Williamson B, Krakauer C, Chau G, Ortiz B, Wakefield J, et al.
Stat Med
. 2022 Jan;
41(6):1120-1136.
PMID: 35080038
In trials of oral HIV pre-exposure prophylaxis (PrEP), multiple approaches have been used to measure adherence, including self-report, pill counts, electronic dose monitoring devices, and biological measures such as drug...
4.
Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al.
N Engl J Med
. 2021 Aug;
385(7):595-608.
PMID: 34379922
Background: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. Methods: We conducted...
5.
Sadik Shaik J, Weld E, Edick S, Fuchs E, Riddler S, Marzinke M, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(4):1667-1678.
PMID: 34240467
Aims: Cabotegravir is an integrase strand transfer inhibitor in clinical development as long-acting (LA) injectable HIV preexposure prophylaxis. Methods: This phase I study assessed pharmacokinetics of cabotegravir in plasma and...
6.
Jayachandran P, Garcia-Cremades M, Vucicevic K, Bumpus N, Anton P, Hendrix C, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Feb;
10(3):179-187.
PMID: 33547874
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prophylaxis product development for sexual transmission of HIV-1. Pharmacokinetic (PK) data from study RMP-02/MTN-006 comparing single dose oral tenofovir...
7.
Stalter R, Baeten J, Donnell D, Spinelli M, Glidden D, Rodrigues W, et al.
Clin Infect Dis
. 2021 Feb;
72(3):486-489.
PMID: 33527128
New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine...
8.
Mboup A, Diabate S, Behanzin L, Guedou F, Zannou D, Keke R, et al.
Sex Transm Dis
. 2021 Jan;
48(8):565-571.
PMID: 33448731
Background: HIV preexposure prophylaxis (PrEP) efficacy is closely linked to adherence, and factors associated with PrEP adherence are not well understood and may differ across populations. As PrEP demonstration projects...
9.
Mboup A, Behanzin L, Guedou F, Giguere K, Geraldo N, Zannou D, et al.
Medicine (Baltimore)
. 2020 Jun;
99(21):e20063.
PMID: 32481273
Background: Measuring adherence to PrEP (pre-exposure prophylaxis) remains challenging. Biological adherence measurements are reported to be more accurate than self-reports and pill counts but can be expensive and not suitable...
10.
Okafor C, Hucks-Ortiz C, Hightow-Weidman L, Magnus M, Emel L, Beauchamp G, et al.
J Acquir Immune Defic Syndr
. 2020 May;
85(1):23-29.
PMID: 32452970
Background: Pre-exposure prophylaxis (PrEP) is efficacious for HIV prevention. Black men who have sex with men (MSM) accounted for the largest proportion of new HIV diagnoses in the United States...